Guillain-Barré syndrome seen in users of isotretinoin
http://www.100md.com
《英国医生杂志》
1 Department of Clinical Neurosciences, Guy's, King's, and St Thomas's School of Medicine, Guy's Hospital, London SE1 1UL, 2 Royal Liverpool Children's NHS Trust, Liverpool, 3 St Thomas's Hospital, London
Correspondence to: J Pritchard jane.pritchard@kcl.ac.uk
We report Guillain-Barré syndrome in people taking oral isotretinoin, a retinoid drug used in secondary care for severe acne.1 The Committee on Safety of Medicines has received one other report of Guillain-Barré syndrome after oral isotretinoin (Committee on Safety of Medicines, private communication).
Case 1—A 31 year old man took 80 mg of oral isotretinoin a day for five weeks, during which he had epistaxis, dry lips, cough, and arthralgia before developing paraesthesiae in his feet and influenza-like symptoms. The next day he could not stand due to an areflexic tetraparesis and needed ventilatory support. Within four days he could only blink.
Case 2—A 13 year old boy took 50 mg of oral isotretinoin a day for two months, stopped for one week, and then took 30 mg a day for six weeks but had epistaxis, lethargy, and headaches. After stopping isotretinoin again for 10 days he developed a flaccid areflexic tetraparesis needing ventilatory support.
Both patients displayed cerebrospinal fluid albuminocytological dissociation. Nerve conduction studies in case 1 showed a motor axonal neuropathy with unrecordable sensory potentials and F waves, those in case 2, done after 21 months, showed borderline increased F wave latencies. Both patients received intravenous immunoglobulin IVIg 2 g/kg and left hospital within three months. Neither patient has been rechallenged with oral isotretinoin, although the first continued to use topical isotretinoin gel 0.05% which is not absorbed.
Retinoids affect the development, differentiation, and function of the central nervous system. Sensory neuropathy has been described in patients taking the retinoid drug acitretin.2 Over a 19 year period, an estimated 375 000 patients have been treated with oral isotretinoin in the United Kingdom (Roche, personal communication), and the annual incidence of Guillain-Barré syndrome is about 2 in 100 000. This is insufficient to establish a causal association between Guillain-Barré syndrome and isotretinoin. We hope to alert others to report similar cases.
We thank the guarantors of Brain.
Funding: JP was funded by a Medical Research Council training fellowship and Brain neurology entry fellowship.
Competing interests: None declared.
References
Webster GF. Acne vulgaris. BMJ 2002;325: 475-9.
Tsambaos D, Sakkis T, Chroni E, Koniavitou K, Monastirli A, Pasmatzi E, et al. Peripheral sensory neuropathy associated with short term oral acitretin therapy. Skin Pharmacol Appl Skin Physiol 2003;16: 46-9.(J Pritchard, neurology re)
Correspondence to: J Pritchard jane.pritchard@kcl.ac.uk
We report Guillain-Barré syndrome in people taking oral isotretinoin, a retinoid drug used in secondary care for severe acne.1 The Committee on Safety of Medicines has received one other report of Guillain-Barré syndrome after oral isotretinoin (Committee on Safety of Medicines, private communication).
Case 1—A 31 year old man took 80 mg of oral isotretinoin a day for five weeks, during which he had epistaxis, dry lips, cough, and arthralgia before developing paraesthesiae in his feet and influenza-like symptoms. The next day he could not stand due to an areflexic tetraparesis and needed ventilatory support. Within four days he could only blink.
Case 2—A 13 year old boy took 50 mg of oral isotretinoin a day for two months, stopped for one week, and then took 30 mg a day for six weeks but had epistaxis, lethargy, and headaches. After stopping isotretinoin again for 10 days he developed a flaccid areflexic tetraparesis needing ventilatory support.
Both patients displayed cerebrospinal fluid albuminocytological dissociation. Nerve conduction studies in case 1 showed a motor axonal neuropathy with unrecordable sensory potentials and F waves, those in case 2, done after 21 months, showed borderline increased F wave latencies. Both patients received intravenous immunoglobulin IVIg 2 g/kg and left hospital within three months. Neither patient has been rechallenged with oral isotretinoin, although the first continued to use topical isotretinoin gel 0.05% which is not absorbed.
Retinoids affect the development, differentiation, and function of the central nervous system. Sensory neuropathy has been described in patients taking the retinoid drug acitretin.2 Over a 19 year period, an estimated 375 000 patients have been treated with oral isotretinoin in the United Kingdom (Roche, personal communication), and the annual incidence of Guillain-Barré syndrome is about 2 in 100 000. This is insufficient to establish a causal association between Guillain-Barré syndrome and isotretinoin. We hope to alert others to report similar cases.
We thank the guarantors of Brain.
Funding: JP was funded by a Medical Research Council training fellowship and Brain neurology entry fellowship.
Competing interests: None declared.
References
Webster GF. Acne vulgaris. BMJ 2002;325: 475-9.
Tsambaos D, Sakkis T, Chroni E, Koniavitou K, Monastirli A, Pasmatzi E, et al. Peripheral sensory neuropathy associated with short term oral acitretin therapy. Skin Pharmacol Appl Skin Physiol 2003;16: 46-9.(J Pritchard, neurology re)